NCT06067776 2023-10-05Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell CancerUniversity of California, DavisPhase 1 Not yet recruiting36 enrolled